National Multiple Sclerosis Society Launches New Funding Program to Shorten Diagnostic Delays
People living with multiple sclerosis face significant delays between their initial symptoms and a definitive diagnosis, a gap the National Multiple Sclerosis Society aims to close through a newly announced funding opportunity reported by News-Medical. While medical treatments have advanced rapidly, slow detection times continue to postpone critical interventions that could improve long-term patient outcomes.
To address this challenge, the organization opened a Request for Applications seeking innovative screening technologies designed to identify individuals likely to have multiple sclerosis within populations already exhibiting elevated risk. The initiative specifically targets scalable, economical, and practical screening tools that can operate smoothly across primary care, specialty care, and community healthcare environments.
Disciplines Invited and Eligible Screening Technologies
Applicants do not need prior experience in multiple sclerosis research. The program actively encourages collaboration across a broad spectrum of scientific and technical fields, including neurology, neuroimmunology, autoimmune disease, ophthalmology, imaging, artificial intelligence, digital health, biomarker discovery, diagnostics development, and data science. Eligible applicants include academic institutions, nonprofit research organizations, and commercial entities.
The funding prioritizes specific technological approaches capable of flagging patients who require a comprehensive neurological evaluation. Acceptable projects include blood-based biomarkers, retinal and visual biomarkers, advanced imaging technologies, digital health measures, and artificial intelligence-enabled or multimodal screening platforms. Conversely, general population risk prediction tools, symptom checkers, basic disease biology research, therapeutic interventions, and implementation science projects fall outside the scope of this grant.
Timeline for Concept Notes and Grant Submissions
The initiative follows a strict three-stage application process administered through the FIRST-MS initiative, which stands for Faster Identification, Recognition, and Screening for Timely MS Diagnosis. Short concept notes mark the first step, with a submission deadline set for December 16, 2026.
Following the initial review, select applicants will receive three-month planning grants before submitting comprehensive full proposals. The timeline proceeds through several distinct milestones:
- December 16, 2026: Concept note submission deadline
- February 1, 2027: Concept note decision notifications released
- June 2, 2027: Full proposal submission deadline
- August 31, 2027: Final award notifications issued
- November 2027: Anticipated start date for awarded projects
A second complementary funding opportunity focusing on risk classification and low-cost identification methods for individuals at elevated risk of developing the disease is slated for release by the National Multiple Sclerosis Society in early 2027.
Frequently Asked Questions About the FIRST-MS Initiative
Who is eligible to apply for the screening technology grants?
Academic institutions, nonprofit research organizations, and commercial companies can apply. Prior research experience in multiple sclerosis is not required, opening the door for experts in artificial intelligence, data science, imaging, and biomarker discovery.
What types of screening approaches are excluded from this funding?
General population risk prediction tools, basic disease biology research, symptom checkers, educational programs, and therapeutic interventions are excluded from the current Request for Applications.
What happens after the initial concept note deadline?
Applicants who pass the first screening will receive three-month planning grants to develop their ideas further before submitting full project proposals by June 2, 2027.
Worth a look